Is corticotropin a controlled substance in the US?

Yes, corticotropin is classified as a Schedule II controlled substance by the DEA due to its corticosteroid effects, not abuse potential. This means it requires a standard prescription from a licensed physician and can only be dispensed by licensed pharmacies. Schedule II classification does not make it illegal; it is a normal regulatory category for many approved medications.

Can I buy corticotropin online without a prescription?

No. Corticotropin requires a valid prescription from a licensed US physician. Any online vendor selling corticotropin without a prescription is operating illegally. Always obtain corticotropin through a licensed pharmacy with a prescription from your doctor.

Why is corticotropin so expensive if it's FDA-approved?

FDA approval guarantees safety and efficacy for labelled indications; it does not regulate pricing. Corticotropin's high cost is driven by manufacturer pricing strategy, limited competition, and the Orphan Drug Designation for infantile spasms, which provides market exclusivity. Many insurers now require prior authorization. Discuss cost concerns with your physician; patient assistance programs may be available.

Is corticotropin approved for all 19 listed conditions with the same strength of evidence?

No. FDA approval does not imply equal evidence for all indications. Corticotropin has the strongest evidence in infantile spasms (a first-line treatment) and weaker evidence for many other approved uses. Your physician will weigh the evidence and clinical context when deciding whether corticotropin is appropriate for your condition.

What is the difference between Acthar Gel and other corticotropin products?

Acthar Gel is the primary FDA-approved corticotropin product currently marketed in the US. It is a repository formulation designed for intramuscular injection. Historically, other corticotropin preparations existed (e.g., synthetic ACTH analogues), but Acthar Gel dominates the US market. Your physician will prescribe the specific formulation they consider appropriate.

Corticotropin Legal Status in the US: FDA Approval & Regulation

Corticotropin is a fully FDA-approved medication in the United States, legally prescribed and dispensed by licensed pharmacies under physician supervision. Sold commercially as Acthar Gel, it's an injectable preparation of ACTH (adrenocorticotropic hormone) that has been in the US pharmacopoeia since the 1950s. The drug carries FDA approval for approximately 19 labelled indications, including infantile spasms, nephrotic syndrome, and multiple sclerosis relapses. Unlike research compounds or investigational agents, corticotropin is a Schedule II controlled substance under the DEA (due to its corticosteroid effects) and requires a standard prescription. Its legal status is unambiguous—what makes corticotropin controversial in the US is not legality, but its extraordinary pricing and ongoing clinical debates about efficacy relative to cheaper alternatives.

Current Legal Status in the US

Corticotropin holds FDA approval and is therefore legal to manufacture, distribute, and prescribe in the United States. The drug is not a research compound, investigational agent, or grey-market product. It is a Schedule II controlled substance under the DEA classification system, which reflects its corticosteroid nature and potential for systemic effects rather than abuse liability. Patients can obtain corticotropin with a valid prescription from a licensed physician through licensed pharmacies.

The brand name formulation Acthar Gel is the primary FDA-approved preparation currently on the market. This is a repository injection designed for intramuscular use, containing 80 units of ACTH per mL.

Regulatory History and Timeline

Corticotropin's regulatory journey in the US spans decades. The hormone was first isolated in the 1930s and entered clinical use in the 1940s–1950s. It received FDA approval long before the modern regulatory framework was fully established, meaning its approval predates the rigorous randomized controlled trial requirements now standard for new drugs.

Key regulatory milestones:

1950s–1970s: Corticotropin was widely used for numerous indications as an alternative to oral corticosteroids, particularly in rheumatology and neurology.
1980s–1990s: As evidence accumulated for oral steroids and other therapies, corticotropin's clinical role narrowed, but it remained approved for its existing indications.
2009: The FDA granted Orphan Drug Designation to Acthar Gel for infantile spasms, reflecting the rare and severe nature of the condition. This designation provided extended market exclusivity and encouraged development of the formulation.
2010s–2020s: Despite continued FDA approval, corticotropin became the subject of intense regulatory and congressional scrutiny due to the manufacturer's aggressive pricing strategy—the price of Acthar Gel escalated from approximately $40 per vial in 2001 to over $38,000 per vial by the mid-2010s.

The Mallinckrodt Antitrust Settlement and Enforcement

While corticotropin itself remains legal and approved, the company marketing Acthar Gel faced significant regulatory action. In 2017, Mallinckrodt Pharmaceuticals (the then-manufacturer) agreed to pay $100 million to settle federal allegations of antitrust violations. The Department of Justice alleged that Mallinckrodt had illegally acquired a potential competing product to suppress competition and protect Acthar's market position.

This settlement did not change corticotropin's legal status but underscored regulatory scrutiny of commercial practices around the drug. The US has also seen:

Congressional investigations into Acthar pricing practices.
Pharmacy benefit manager (PBM) restrictions on coverage and reimbursement, despite the drug's legal status.
Medicare spending reviews: Spending on Acthar reached approximately $1–2 billion annually at peak, prompting policy discussions.

These enforcement actions targeted business conduct, not the legality of the drug itself.

Clinical Evidence and FDA-Approved Indications

Corticotropin carries FDA approval for approximately 19 conditions. The strongest evidence supports its use in:

Infantile spasms (West syndrome): Considered a first-line treatment, with corticotropin demonstrating efficacy in stopping seizures in infants. This is the indication with the highest-quality evidence and remains the most defensible use.
Nephrotic syndrome: Historical approval, though modern evidence favours oral steroids.
Multiple sclerosis relapses: Approved indication, though modern MS disease-modifying therapies have largely displaced ACTH from routine use.
Rheumatoid arthritis, systemic lupus erythematosus, and other rheumatologic conditions: Historical approvals with weaker modern evidence.

The approval list also includes adrenocortical insufficiency (Addison's disease), though this is not a common indication. The evidence grade for corticotropin is A across the PeptideTrace database, reflecting FDA approval, but this masks heterogeneity: evidence is robust for infantile spasms and weaker for many other indications.

Over 185 clinical trials have investigated corticotropin, though many are historical. Recent trials have focused on infantile spasms and specific autoimmune conditions.

Regulatory Framework: Prescription Requirements

As an FDA-approved medication, corticotropin is subject to standard pharmaceutical regulations:

Prescription requirement: Only licensed physicians can prescribe; it cannot be obtained over-the-counter or without a valid prescription.
Pharmacy dispensing: Only licensed pharmacies can dispense corticotropin.
Insurance and reimbursement: Coverage varies by insurance plan, Medicaid, and Medicare. Many plans have implemented restrictions or require prior authorization due to the drug's high cost.
Labelling and FDA enforcement: The drug must comply with FDA labelling requirements. Any off-label prescribing is legal but at the discretion of the treating physician.
Adverse event reporting: Physicians and pharmacists are required to report serious adverse events to the FDA via MedWatch.

What Consumers and Patients Should Know

Legal status clarity: If a physician has prescribed corticotropin, the prescription is legal and legitimate. There is no grey area here—it is a licensed, approved medication.

Cost and access challenges: Although legal, corticotropin is extremely expensive. Many patients face barriers to access due to:

High out-of-pocket costs.
Insurance denials or prior authorization requirements.
Limited coverage by Medicaid programs in some states.

Patients struggling with access should work with their physician's office, contact patient assistance programs, or consult a pharmacist about generic or alternative options.

Clinical context: The FDA approval of corticotropin does not mean it is the best treatment for every labelled indication. Physicians weigh corticotropin against alternatives (especially far cheaper oral corticosteroids) based on individual patient factors. For infantile spasms, corticotropin remains a recognized first-line option. For many other approved uses, oral steroids or other therapies may be preferred.

Off-label use: Physicians can legally prescribe corticotropin off-label for conditions not listed in the FDA approval. However, off-label prescribing carries the responsibility of the physician; insurance coverage may be withheld.

Regulatory Status Across Other Jurisdictions

For reference, corticotropin's legal status differs internationally:

European Union: Not authorized by the EMA (European Medicines Agency). A similar ACTH product, Synacthen, is available in Europe.
Canada: Not approved by Health Canada.
United Kingdom and Australia: Limited or no availability through standard regulatory pathways.

The US remains one of the few high-income countries where corticotropin is actively marketed and reimbursed, partly due to the Orphan Drug Designation for infantile spasms.

Key Takeaways

Corticotropin is unambiguously legal in the US under FDA approval. It is not a research compound, investigational agent, or controlled substance in the sense of being restricted from medical use. The regulatory questions that have emerged are not about legality but about pricing practices, market competition, and appropriate clinical use relative to alternatives.

If you or a loved one has been prescribed corticotropin by a licensed physician, the prescription is legal. If you have concerns about cost, efficacy, or alternatives, discuss them openly with your healthcare provider. If you're curious about the clinical evidence supporting a specific indication, speak with your pharmacist or physician, who can contextualize the FDA approval within current medical practice.

For deeper dives into specific conditions treated with corticotropin, explore related peptides like tetracosactide (the European equivalent) or learn more about ACTH biology and peptide regulation in the US.

Corticotropin Legal Status in the United States